Document Type
Article
Publication Date
5-12-2017
Publication Title
PloS One
Department
Geisel School of Medicine
Abstract
Development of a tuberculosis vaccine to boost BCG is a major international health priority. SRL172, an inactivated whole cell booster derived from a non-tuberculous mycobacterium, is the only new vaccine against tuberculosis to have demonstrated efficacy in a Phase 3 trial. In the present study we sought to determine if a three-dose series of DAR-901 manufactured from the SRL172 master cell bank by a new, scalable method was safe and immunogenic.
DOI
10.1371/journal.pone.0175215
Original Citation
von Reyn CF, Lahey T, Arbeit RD, Landry B, Kailani L, Adams LV, Haynes BC, Mackenzie T, Wieland-Alter W, Connor RI, Tvaroha S, Hokey DA, Ginsberg AM, Waddell R. Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: A randomized, controlled trial of DAR-901. PLoS One. 2017 May 12;12(5):e0175215. doi: 10.1371/journal.pone.0175215. PMID: 28498853; PMCID: PMC5429024.
Dartmouth Digital Commons Citation
von Reyn, C. Fordham; Lahey, Timothy; Arbeit, Robert D.; Landry, Bernard; Kailani, Leway; Adams, Lisa; Haynes, Brenda; Mackenzie, Todd; Wieland-Alter, Wendy; Connor, Ruth; Tvaroha, Sue; Hokey, David; Ginsberg, Ann; and Waddell, Richard, "Safety and Immunogenicity of an Inactivated Whole Cell Tuberculosis Vaccine Booster in Adults Primed with BCG: A Randomized, Controlled Trial of DAR-901" (2017). Dartmouth Scholarship. 1719.
https://digitalcommons.dartmouth.edu/facoa/1719
